410 related articles for article (PubMed ID: 31478786)
21. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
23. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
[TBL] [Abstract][Full Text] [Related]
24. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
[TBL] [Abstract][Full Text] [Related]
25. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
Kocsis B; Domokos J; Szabo D
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
[TBL] [Abstract][Full Text] [Related]
26. Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates.
Ostrer L; Khodursky RF; Johnson JR; Hiasa H; Khodursky A
Int J Antimicrob Agents; 2019 Mar; 53(3):318-324. PubMed ID: 30582984
[TBL] [Abstract][Full Text] [Related]
27. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
[TBL] [Abstract][Full Text] [Related]
28. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
29. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.
Liu YH; Kuo SC; Lee YT; Chang IC; Yang SP; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Apr; 45(2):108-12. PubMed ID: 22153765
[TBL] [Abstract][Full Text] [Related]
30. Presence of plasmid-mediated quinolone resistance determinants and mutations in gyrase and topoisomerase in Salmonella enterica isolates with resistance and reduced susceptibility to ciprofloxacin.
Casas MR; Camargo CH; Soares FB; da Silveira WD; Fernandes SA
Diagn Microbiol Infect Dis; 2016 May; 85(1):85-9. PubMed ID: 26971183
[TBL] [Abstract][Full Text] [Related]
31. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
32. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
33. Substitutions of Ser83Leu in GyrA and Ser80Leu in ParC Associated with Quinolone Resistance in Acinetobacter pittii.
Gu DX; Hu YJ; Zhou HW; Zhang R; Chen GX
Microb Drug Resist; 2015 Jun; 21(3):345-51. PubMed ID: 25514581
[TBL] [Abstract][Full Text] [Related]
34. Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an
Huang J; Guo S; Li X; Yuan F; Li Y; Xu B; Gu J; Qiao Y
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0180021. PubMed ID: 34902266
[TBL] [Abstract][Full Text] [Related]
35. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
36. Fluoroquinolone resistance linked to both gyrA and parC mutations in the quinolone resistance-determining region of Shigella dysenteriae type 1.
Talukder KA; Khajanchi BK; Islam MA; Islam Z; Dutta DK; Rahman M; Watanabe H; Nair GB; Sack DA
Curr Microbiol; 2006 Feb; 52(2):108-11. PubMed ID: 16450072
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Lister PD
Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
[TBL] [Abstract][Full Text] [Related]
38. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
39. [MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones].
Malakhova MV; Vereshchagin VA; Il'ina EN; Govorun VM; Filimonova OIu; Grudinina SA; Sidorenko SV
Antibiot Khimioter; 2007; 52(1-2):10-7. PubMed ID: 18461803
[TBL] [Abstract][Full Text] [Related]
40. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
Yang J; Luo Y; Cui S; Wang W; Han L
Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]